作者投稿
专家审稿
编辑办公
邮件订阅
RSS
Pathogens and Antibiotic Resistance of Isolates from Patients with Urinary Tract Infections in Peking Union Medical College Hospital, 1990-2009
-
摘要:
目的 了解住院患者尿道细菌感染常见病原菌及其对抗菌药物的耐药性。 方法 用纸片扩散法对1990-2009年北京协和医院住院患者尿道感染分离的4565株病原菌进行抗菌药物耐药监测。 结果 20年来北京协和医院住院患者尿道感染以大肠埃希菌检出率最高(33%), 其次为粪肠球菌(12%)、屎肠球菌(8%)、凝固酶阴性葡萄球菌(7%)、铜绿假单胞菌(6%)和肺炎克雷伯菌(6%)。2006-2009年产超广谱β-内酰胺酶(extended-spectrum beta-lac-tamases, ESBLs)的大肠埃希菌检出率为60%;大肠埃希菌对亚胺培南、美罗培南和厄他培南均100%敏感, 对环丙沙星和左氧氟沙星的耐药率为77.7%和76.4%。粪肠球菌对呋喃妥因和磷霉素的耐药率均低于10%。 结论 住院患者尿道感染最常见的病原菌是大肠埃希菌, 且细菌耐药性呈增长趋势, 临床上应加强细菌耐药监测。 Abstract:Objective To identify the common pathogens of urinary tract infections and the potential existence of drug resistance. Methods A total of 4565 clinical isolates from patients with urinary tract infections were collected in Peking Union Medical College Hospital from 1990 to 2009. Antimicrobial susceptibility was detected by disk diffusion method. Results The most common pathogen identified was E. coli (33%), followed by Enterococcus faecalis (12%), Enterococcus faecium (8%), coagulase negative staphylococcus (7%), Pseudomonas aeruginosa (6%), and Klebsiella pneumoniae (6%). Extended-spectrum beta-lactamases (ESBLs)-producing strains in E. coli isolate was 60% from 2006 to 2009. Strains of E. coli and K. pneumoniae were still highly susceptible to imipenem, meropenem, and ertapenem. The resistance rates of E. coli strains to ciprofloxacin and levofloxacin were 77.7% and 76.4%, respectively. The resistance rates of E. faecalis to nitrofurantoin and fosfomycin were lower than 10%. Conclusion E. coli is the main cause of urinary tract infection. Bacterial resistance remains a major concern and more efforts should be made in the monitoring of drug resistance. -
Key words:
- urinary tract infection /
- pathogenic bacterium /
- bacterial resistance
-
表 1 粪肠球菌、屎肠球菌和凝固酶阴性葡萄球菌对常用抗菌药物的耐药率(%)
表 2 大肠埃希菌、肺炎克雷伯菌和铜绿假单胞菌对常用抗菌药物的耐药率(%)
表 3 四年份段大肠埃希菌对某些抗菌药物的耐药率(%)
-
[1] Clinical and Laboratory Standards Institute (CLSI). M100S20Performance standards for antimicrobial susceptibility testing[S]. 2010. [2] Stamm WE, Norrby RS. Urinary tract infections: disease panorama and challenges[J]. J Infect Dis, 2001, 183: S1S4. [3] WHO. Epidemiology of nosocomial infections[M] // WHO. Prevention of hospital acquired infections: a practical guide. 2nd ed. Geneva: WHO, 2002: 5. [4] Matsumoto T, Muratani T. Newer carbapenems for urinary tract ifections[J]. Int J Antimicrob Agents, 2004, 24: S35-S38. https://www.sciencedirect.com/science/article/pii/S0924857904000925 [5] Piddock LJ. Mechanisms of fluoroquinolone resistance: an update 1994-1998[J]. Drugs, 1999, 58: S11-S18. http://cn.bing.com/academic/profile?id=3eb15cc88c45182c70ea502252706f9d&encoded=0&v=paper_preview&mkt=zh-cn [6] Nordmann P, Poirel L. Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae[J]. J Antimicrob Chemother, 2005, 56: 463-469. doi: 10.1093/jac/dki245 [7] Lautenbach E, Fishman NO, Bilker WB, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections[J]. Arch Inern Med, 2002, 162: 2469-2477. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhlcgrbzz201205006 [8] Olson RP, Harell UJ, Kaye KS. Antibiotic resistance in urinary isolates of Escherichia coli from college women with urinary tract infections[J]. Antimicrob Agents Chemother, 2009, 53: 1285-1286. [9] Javiya VA, Ghatak SB, Patel KR, et al. Antibiotic susceptibility patterns of Pseudomonas aeruginosa at a tertiary care hospital in Gujarat[J]. Indian J Pharmacol, 2008, 40: 230-234. doi: 10.4103/0253-7613.44156 [10] Thean YT, Siew YN, Wan XN. Clinical significance of coagulase-negative staphylococci recovered from nonsterile sites[J]. J Clin Microbiol, 2006, 44: 3413-3414. doi: 10.1128/JCM.00757-06 -
点击查看大图
表(3)
计量
- 文章访问数: 160
- HTML全文浏览量: 65
- PDF下载量: 8
- 被引次数: 0
下载:
